Introduction
With annual revenues of over $2.6 billion in 2004, and a compound annual growth rate of 36.7% since 2002, the ADHD market is one of the most rapidly growing CNS markets. This growth is primarily attributed to the launches of several novel, once-daily ADHD therapies initially in the US and then periodically across the remaining major markets since 2000.
Scope of this report
- Overview of current market including profiles of key brands and key events impacting each brand during 2004-2005
- Assessment of current and future opportunities and threats in the ADHD market across the seven major pharmaceutical markets
- Global sales for leading ADHD products from 2002-2004 are presented, with projections for future performance up to 2015
- In-depth discussion of assumptions and events used in forecast analysis
Research and analysis highlights
US revenue growth within the ADHD market follows a distinct annual cycle, with the highest revenue growth occurring in August and September, coinciding with the end of the school summer vacation. Manufacturers wishing to maximize revenue potential on drug launch should therefore take advantage of this period of high drug revenue growth.
Drugs licensed for the treatment of adult ADHD are driving growth in this sector of the market, and derive significantly greater revenue shares as compared to drugs that are used off-label. Datamonitor believes that now is an ideal time for manufacturers to gain approval for adult ADHD in the US, and enter this expanding market.
Strattera was the most rapidly growing drug in the US ADHD market with 2004 revenues of $632m, However, Q1 2005 revenues of the drug fell by 25.1% over Q4 2004, as a result of a product warning and other adverse market events. Nevertheless, Datamonitor forecasts that Strattera will bounce back and become market leader form 2007 onwards.
Key reasons to read this report
- Assess leading ADHD drugs and identify key success factors within this sector
- Understand key market drivers and predict the future performance of key compounds
- Benchmark pipeline ADHD drugs against currently marketed products and assess their future market potential
View Cart
